TREACE MEDICAL CONCEPTS, INC.
Company Stats
- Market Cap
- $288.8M
- as of Sep 30, 2026
- Enterprise Value
- $338.0M
- Shares Outstanding
- 65.0M
- Free Float
- 52.7%
Income Statement
- Revenue
- $212.7M
- Operating Income
- -$54.2M
- Net Income
- -$59.0M
- EBITDA
- -$43.5M
- Revenue Growth, 3Y
- 14.5%
- FCF Margin, 3Y Avg
- -20.6%
- FCF Margin, Worst Year
- -24.6%
Cash Flow
- Free Cash Flow
- -$29.5M
- FCF Yield
- -10.2%
- Owner FCF Yield
- -21.9%
Balance Sheet
- Cash & Equivalents
- $10.7M
- Total Debt
- $60.0M
- Net Debt
- $49.3M
Returns & Capital
- SBC, 3Y Avg
- $27.3M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $212.7M | -$29.5M | -13.9% |
| FY2024 | $209.4M | -$48.8M | -23.3% |
| FY2023 | $187.1M | -$46.0M | -24.6% |
| FY2022 | $141.8M | -$45.5M | -32.1% |
| FY2021 | $94.4M | -$19.9M | -21.1% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 13, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back